MARKET

DMAC

DMAC

DIAMEDICA THERAPEUTICS INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.85
-0.07
-0.94%
Opening 11:09 07/02 EDT
OPEN
6.92
PREV CLOSE
6.91
HIGH
6.92
LOW
6.80
VOLUME
7.80K
TURNOVER
--
52 WEEK HIGH
8.80
52 WEEK LOW
1.700
MARKET CAP
96.78M
P/E (TTM)
-8.5402
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DMAC stock price target is 12.33 with a high estimate of 15.00 and a low estimate of 8.00.

EPS

DMAC News

More
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
Hedge Funds Getting Interested In DiaMedica Therapeutics Inc. (DMAC)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These fi
Insider Monkey · 06/11 00:16
DiaMedica Therapeutics to Present at the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 17th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, May 27, 2020. Management will be available to participate in one-on-on
Business Wire · 05/19 20:42
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $15
Craig-Hallum maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $10 to $15.
Benzinga · 05/15 15:47
60 Biggest Movers From Yesterday
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares surged 71.1% to close at $15.21 on Thursday after the company announced it has received FDA emergency use authorization for its coronavirus diagnostic assay kit.
Benzinga · 05/15 08:53
42 Stocks Moving In Thursday's Mid-Day Session
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) jumped 53.4% to $13.64 after the company announced it has received FDA emergency use authorization for its coronavirus diagnostic assay kit.
Benzinga · 05/14 18:57
DiaMedica Therapeutics Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/14 16:46
AIM, CLLS, CRK and CGEN among midday movers
Seeking Alpha - Article · 05/14 16:40

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.45%

Hot Stocks

Symbol
Price
%Change

About DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins. The Company uses its technologies for the development and commercialization of recombinant proteins to treat kidney and neurological diseases. The Company’s focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). The Company’s lead product DM199, is a drug candidate, a commercial potential as a therapy for CKD and AIS. DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands that plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in inflammation and oxidative stress.
More

Webull offers kinds of DiaMedica Therapeutics Inc stock information, including NASDAQ:DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.